By SPC News Staff
The FDA granted a new indication for pemigatinib (Pemazyre, Incyte) to treat adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement.
Pemigatinib received accelerated FDA approval in 2020 for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement.
Pemigatinib is a selective fibroblast growth factor receptor inhibitor. The
AUGUST 30, 2022